66results about How to "Promote absorption in the body" patented technology

A breviscapine-phosphotide composition in the form of oral preparation or injection is prepared from breviscapine and soybean (or egg yolk, or synthetic) lecithine in a wt ratio of 1:(0.5-50) through heating, reflux, washing and drying. Its advantages are high stability and durability, and quickly taking its curative effect.

The present invention relates to dutasteride liquid soft capsules and a preparation method thereof. The soft capsules comprise a capsule shell and contents, wherein the contents mainly comprise, by weight, 0.05-0.3% of dutasteride, 19.8-94.8% of medium chain triglyceride, and 5-80% of mono-caprylin glycerate. The soft capsules have characteristics of rapid dissolution, simple preparation process and the like.

The invention relates to a loaded aprepitant nanocrystal lipid microcapsule and a preparation method thereof, and belongs to the technical field of a medicine. The microcapsule is prepared by the method comprising the following steps: preparing an aprepitant nanocrystal from aprepitant by virtue of a grinding process, high-speed air jet pulverization or high-pressure homogenization, then mixing and emulsifying the aprepitant nanocrystal with phospholipid, removing a liquid phase and drying so as to obtain the aprepitant nanocrystal lipid microcapsule. The prepared loaded aprepitant nanocrystal lipid microcapsule can improve the stability of the aprepitant nanocrystal and the lipid loaded nanocrystal can increase the speed and the amount of being absorbed by gastrointestinal mucosa of a body, so that the effects of relatively high bioavailability and accelerated development of efficacy are achieved; and the preparation method of the loaded aprepitant nanocrystal lipid microcapsule is mild in condition, simple and controllable, low in preparation cost and is suitable for large-scale production.

The invention provides itraconazole nanocrystals and a preparation method and application thereof. Acid phase in which itraconazole is dissolved is dropwise added into alkaline phase to over-saturate the itraconazole; the itraconazole molecules are aggregated into amorphous nanocrystalline particles in the presence of a high molecular stabilizer to form a stable structure with itraconazole nanocrystals as a core and the high molecular stabilizer as a shell; and both the solubility and the dissolution rate of the itraconazole nanocrystals are greatly improved compared with those of normal itraconazole nanoparticle suspension. A hydrophilic fragment of the high molecular stabilizer, which is extended into the water, improves the hydrophobicity of the surfaces of the itraconazole nanoparticles, so that the high molecular stabilizer is more easily moistened and dissolved; and the high molecular stabilizer serving as the shell enhances the adhesion between the medicament particles and gastrointestinal mucous membrane, is favorable for improving the bioavailability and reduces the influence of a diet state on the bioavailability. The method of the invention has the advantages of no use of toxic solvent, simple preparation process, low cost and easy industrialization.

The invention provides an oral ciclosporin A sustained-release agent. The sustained-release agent comprises the following components in part by mass: 1 part of ciclosporin A, 2.5 to 7.5 parts of polyvidone-K30, 0.15 to 4.82 parts of hydroxypropyl methyl cellulose 4000cPa.s, 0.1 to 3.94 parts of microcrystalline cellulose, 0 to 2.57 parts of hydroxypropyl methyl cellulose 15000cPa.s and 0.1 to 1.0part of phospholipid. By combining a solid dispersing technology and a sustained-release hydrophilic gel matrix technology and based on the 'double release' principle of fast release first and slow release second, the method prepares the insoluble medicament of ciclosporin A sustained-release agent; and the method has the obvious advantages that the solubility of ciclosporin A is improved, and the oral agent can quickly play the effect first and then smoothly and slowly release drug. The ciclosporin A sustained-release tablets reduce the lowered blood concentration peak-valley phenomenon and lower the drug-taking frequency. The invention also discloses a method for preparing the oral ciclosporin A sustained-release agent.

The invention discloses a method preparing a capsaicin-loaded pH sensitive gel microsphere, and the gel microsphere prepared by the same. According to the method, the capsaicin-loaded pH sensitive gel microsphere is prepared by regulating the proportion and concentrations of capsaicin taken as a raw material medicine and carboxymethyl chitosan and sodium alginate with excellent biodegradability, biocompatibility and low toxicity as a carrier material. According to the gel microsphere, the drug loading capacity can be (18.06+/-0.26) percent, the encapsulation efficiency is (97+/-3.66) percent, the release of the gel microsphere in a medium with the pH value of 7.8 is remarkably superior to those in environments with pH values of 1.2, pH 4.8 and pH 6.8, and the gel microsphere has remarkable pH sensitivity and potential colonic targeting trend. Furthermore, after the gel microsphere is administrated in an oral manner, drugs can be multiply transferred step by step to the optimal absorption part along with changes of the pH value of gastrointestinal tracts, and certain characteristics of delayed release and sustained release can be reflected, so that in-vivo absorption of capsaicin can be improved, the bioavailability can be improved, and irritation of the capsaicin to gastric mucosa can be reduced.

The invention discloses a self-microemulsion nutrient composition containing coenzyme Q10 and a preparation method and application. The self-microemulsion nutrient composition comprises the following components in parts by weight: 1-15 parts of coenzyme Q10, 1-15 parts of curcumin, 10-50 parts of carrier oil, 15-75 parts of a nonionic surfactant, 1-5 parts of a cationic gemini surfactant, 5-30 parts of a cosurfactant and 0-2 parts of an antioxidant, wherein the components are prepared into a uniform, stable, clear and transparent solution. The self-microemulsion nutrient composition has good stability, crystallization of coenzyme Q10 is remarkably inhibited, and the product shelf life is prolonged. In the application process, the composition can be simply and conveniently added into systems of water-phase food, medicines and the like according to demand amounts, and is safe and effective. Meanwhile, the whole preparation process is green, environmental-friendly, low in energy consumption and easy in industrial production.

The invention relates to suspension containing andrographolide solid lipid nanoparticles as well as a preparation method and an application of the suspension, wherein the andrographolide solid lipid nanoparticles are dispersed in emulsion formed by purified water and emulsifying agents and consists of andrographolide and lipid materials, the weight ratio of the andrographolide to the lipid materials to the emulsifying agents is (1-15): (35-70):(20-50), and the consumption of the purified water is metered according to the principle that 1ml of purified water is added into 5 to 20mg of emulsifying agents. The suspension has the advantages that the andrographolide is covered and sealed in lipid inner cores of the solid lipid nanoparticles, the in-vivo absorption of the medicine is improved, the bioavailability is improved, meanwhile, and the slow release performance and the targeting performance are realized, so the toxic or side effect is reduced, and the anti-tumor curative effect is improved.

The invention belongs to the field of medicine preparations and relates to a formula of a lipid carrier of curcumin in a nano structure and a preparation method of the lipid carrier. The lipid carrier of curcumin in the nano structure extremely overcomes the deficiencies that curcumin is difficult to be dissolved in water, low in oral bioavailability, fast in metabolism and the like, provides a novel selectable transfer system for curcumin and has important meaning.

The invention relates to a Cyclosporin A rapidly releasing solid dosage forms in the medicine technical field and the preparation method. The components weight contents of the solid dosage forms of the invention are that: 0.5 to 5 percent CyA, 5 to 75 percent lipide, and 5 to 70 percent porosint. The invention adopts CyA as the medicine activity component which is dissolved in the heating meltdown lipid material and added with the porosint in order to be richly adsorbed, then solid combined powder is prepared to be further suppressed to tablet or filled into capsule. The moisture content of the invention permeates into the porosint as meeting with water so as to make the wrapped medicine-lipide dispersoid inflate by absorbing water, pile out the gape structure and the medicine can be released. The invention can amplify the solubility and stripping speed of CyA, is useful for the absorption of medicine, has good stability, prevents the uses of organic solvent and polyoxyethylene castor oil, has safe operation, reduces the poison as well as side effects of medicine and has immunological rejection resisting function.

The invention discloses a compound shown in a general formula (I) or pharmaceutically acceptable salt of the compound and preparation methods of the compound and the salt, and further discloses pharmaceutical composition containing the compound and an application of the compound and the pharmaceutical composition in preparation of an AXL inhibitory drug. The AXL inhibitory drug is used for treating tumor, nephropathy, immune system disease or circulatory system disease.

The invention discloses a tripterine nanostructure lipid carrier modified by lentiviral vector and preparation method and application thereof, wherein teh tripterine nanostructure lipid carrier modified by the lentiviral vector consists of tripterine and a lipid carrier, various components comprise 1 part by weight of tripterine, 0.5 to 10 parts by weight of lentiviral vector, 5 to 100 parts by weight of lipid blends, 0.5 to 20 parts by weight of emulsifier and 5 to 100 parts by weight of stabilizer. The tripterine nanostructure lipid carrier modified by the lentiviral vector can increase nanoparticles encapsulating rate to 78-90%. The tripterine nanostructure lipid carrier modified by the lentiviral vector uses oral administration, thereby promoting absorbing of the tripterine in a body,improving bioavailability, reducing administration dosage, reducing accumulation of the tripterine in the body at last, reducing toxic reaction by combining sustained release of a nanostructure lipidcarrier, and improving clinical therapeutic effect of the tripterine at last.

The invention discloses an atorvastatin calcium and phospholipid compound. The atorvastatin calcium and phospholipid compound is prepared from atorvastatin calcium and phospholipid, wherein the mol ratio of the atorvastatin calcium to the phospholipid is (1-4) to (4-1); the concentration of reactants is 0.1mg/ml-10mg/ml; and the phospholipid is selected from at least one of natural soybean phospholipid, natural lecithin or artificially synthetic phosphatidylcholine, phosphatidylglycerol, phosphatidylethanolamine, phosphatidylserine and phosphatidic acid. According to the atorvastatin calcium and phospholipid compound and a preparation method, disclosed by the invention, structural features of insoluble drugs are improved from a molecular level, so that the aims of improving the permeability and increasing the oral bioavailability are realized.

The invention discloses a processing method for increasing the solubility and the bioavailability of a fat-soluble active component and belongs to the technical field of processing of modern nutritional foods.Water-soluble starch particles are used as carriers, and a nanoscale fat-soluble active component-starch particle compound is prepared with a nano suspension technology, so that the water solubility as well as absorption and utilization effects of the fat-soluble active component are improved. The method can significantly increase the solubility and the bioavailability of insoluble food active components and can be applied to various fields of foods, medicines, daily chemicals and the like.

The invention provides a method for preparing angelica dahurica decoction pieces. The method comprises the following steps: (1) grinding a medicinal material such as angelica dahurica into coarse powder; and (2) drying the coarse powder prepared by the step (1), grinding at 12 to 16 DEG C for 20 minutes in a Bailey supermicro pulverizer BFM-100B till a particle size of 300 to 500 meshes. The invention also provides angelica dahurica decoction pieces prepared by the method. The angelica dahurica decoction pieces prepared by the method have the advantages that: after the supermicro medicinal material is ground on a cell level, the surface area is greatly increased, and active ingredients dissolve out quickly; meanwhile, the active ingredients can well contact gastrointestinal mucosa, so theabsorption is easier, the bioactive is retained and medicinal effect is enhanced; and the angelica dahurica super micro powder obtained by the method can ensure good absorption in vivo when the particle size is between 300 and 500 meshes, so the energy consumed in the supermicro grinding process of the angelica dahurica is reduced greatly.

The invention relates to an absorbable hemostasis composite material based on polyanionic cellulose, and a preparation method of the absorbable hemostasis composite material. The absorbable hemostasis composite material is obtained in a way that a network structure is established by taking the polyanionic cellulose as a base material, and then, the network structure carries out electrostatic adsorption self-assembling with chitosan or chitosan derivatives or carries out electrostatic self-assembling with the chitosan or the chitosan derivatives to load protein polypeptide, or the absorbable hemostasis composite material is obtained in a way that the network structure is established by taking the polyanionic cellulose as the base material, chitosan microspheres or chitosan microspheres and the protein polypeptide are subjected to in situ pelletizing, and then, loading is carried out on the surface and the network of the cellulose. The absorbable hemostasis composite material has the characteristics of acute hemostasis, broad-spectrum bacteria resistance, healing acceleration and in vivo absorption.

The invention discloses a preparation method of a full-ingredient active ginseng lyophilized product. According to the method, a fresh ginseng is used as a main raw material; advanced technical measures such as a high-pressure bubble cleaning technology, a part-of-tissue shearing and wall breaking technology, a ginseng anaerobic endophytic bacteria bioconversion-ginseng aerobiotic endophytic fungi bioconversion-ginsenosidase conversion combined conversion technology, a centrifugal separation technology, an ultrasonic sterilization technology and a lyophilizing technology; compared with a conventional ginseng processing product preparation method such as drying, steaming and high-temperature extraction, the method has the advantages that the prepared full-ingredient active ginseng lyophilized product has the characteristics of complete retention of active ingredients of the ginseng, high rare ginsenosides content, rapid oral absorption, high biological utilization rate and the like. The product retains the cold and moistening nature of the ginseng; compared with dried and other ginseng processing products with relatively high dryness, the full-ingredient active ginseng lyophilized product has the distinct characteristic that the product is cold but not causing the dryness. A technical support can be provided for upgrading the ginseng industry in China.

The invention belongs to the novel technology field of the medicines and relates to a novel dosage form of ceftibuten for treating: upper respiratory tract infection such as pharyngitis, antiaditis, scarlet fever, paranasal sinusitis, and otitis medium; lower respiratory tract infection such as acute bronchitis, acute attack of chronic bronchitis and pneumonia; urinary tract infection; enteritis and gastroenteritis. The dosage form is characterized in that the dosage form is dispersing tablets, and can disintegrate quickly into fine granules when encountering water, and the granules uniformly disperse and can pass through size 2 sieve (24 mesh). Preparing the medicines with small dose and low water-solubility into the dispersing tablets can obviously improve absorption in vivo and improve bioavailability.

The invention relates to the technical field of medicinal oral solid preparations, in particular to a medicinal composition of a methanesulfonic acid arbidol oral solid preparation serving as an anti-influenza virus medicament. The composition exists in the form of film-coated tablets, dispersible tablets, chewable tablets, capsules or particles; the film-coated tablets, dispersible tablets, chewable tablets, capsules or particles consist of an effective dosage of methanesulfonic acid arbidol and excipient; and the excipient contains organic acid for enhancing the stability of the medicinal composition, and contains more than three of a diluent, a bonding agent, a disintegrating agent, a flavoring agent and a lubricant. The medicinal composition has the advantages of stable mass, reasonable formula, application of nontoxic excipient, high safety, small using amount of auxiliary materials, capability of meeting the requirement of the oral solid preparation, quick dissolving of all dosage forms, medicament dissolving rate over 85 percent within 15 minutes, contribution to in-vivo absorption of the oral solid preparation and guarantee of better curative effect.

The invention discloses the composition of tall gastrodia tuber and lecithin, and a preparation method thereof. The composition is prepared by mixing tall gastrodia tuber extract and the lecithin according to the mass ratio of 10:90 to 95:5, wherein the tall gastrodia tuber extract is whole tall gastrodia tuber powder or the alcohol extract of medicinal parts of the tall gastrodia tuber; the lecithin is egg yolk lecithin or soybean lecithin; and the alcohol extract is powder obtained by refluxing and extracting the whole tall gastrodia tuber powder or the alcohol extract of the medicinal parts of the tall gastrodia tuber by using 30 to 90 volume percent ethanol, collecting extract, concentrating the extract into paste and drying and crushing the paste. The composition is prepared by compounding the tall gastrodia tuber extract and the lecithin, is rational in formula, advanced in process, safe and effective, has complementary functions and the effects of invigorating the brain and tolerating hypoxia, supplements neural transmitting substances by the lecithin, and simultaneously has the central nervous system depression function of the tall gastrodia tuber extract and the functions of improving the anaerobic condition of a human body, particularly the brain, and protecting the brain from damage.

The invention belongs to the field of medicines, and relates to a new application of cistanche polysaccharides and a pharmaceutical composition with the same, in particular to application of cistanchepolysaccharides for preparation of a medicament for promoting in vivo absorption of phenylethanoid glycosides. The invention also relates to a pharmaceutical composition containing cistanche polysaccharides as an active ingredient, a phenylethanoid glycoside compound and/or a plant extract containing a phenylethanoid glycoside compound. Cistanche polysaccharides can effectively promote the in vivo absorption of phenylethanoid glycosides. The pharmaceutical composition disclosed by the invention has an estrogen-like action and is effective for treating and/or preventing osteoporosis.

The invention relates to an amorphous form of avanafil, a preparation method, application and a medicine composition of the amorphous form of avanafil. The amorphous form of avanafil has no obvious characteristic peak in powder X-ray diffraction pattern based on Cu-K alpha radiation and shows a valuable characteristic in drug preparation; the amorphous form is high in purity and stable, and the in-vivo absorption of the amorphous form is superior to that of a crystal form.

A composite medicine in the form of tablet, capsule, suspension, or injection for protecting liver is prepared from oleanolic acid, surfactant and water. Its preparing process is also disclosed.

The invention provides application of luteolin to the preparation of a medicine for treating an oxidative stress injury of testicular tissue, and relates to the field of male reproduction and endocrinic medicines. An active component of a medicinal composition is the luteolin. Discovered through an experiment, the injury, which is caused by hydrogen peroxide and triptolide, of a testicular sustentacular cell can be reversed through the intervention treatment of the luteolin; the apoptosis of the testicular sustentacular cell induced by the hydrogen peroxide is inhibited; the accumulation of ROS (Reactive Oxygen Species) is inhibited; the collapse of a cellular mitochondrial membrane potential caused by the hydrogen peroxide is reversed; the expression of a downstream antioxidase gene can be activated; the autologous oxidation-resistance capacity of the sustentacular cell is improved; the injury to the testicular tissue of a mouse induced by the triptolide is effectively reversed. Besides, the luteolin can be also used for inhibiting the increment of the permeability of a blood-testis barrier, which is caused by the triptolide-induced oxidative stress injury, through regulating and controlling gap junction, occlusion junction and tight junction protein; the completeness of the blood-testis barrier is protected. Therefore, the luteolin can be applied to the preparation of the medicine for treating the oxidative stress injury of the testicular tissue.

The invention provides a self-emulsifying EPA (eicosapentaenoic acid) nutrient composition and an application thereof. The self-emulsifying EPA nutrient composition comprises, by weight, 30-85% of EPA, 10-70% of grape seed extract, 0.002-0.04% of vitamin K2, and 4-10% of an emulsifier. The self-emulsifying EPA nutrient composition has a substantial arthritis treatment effect, has small toxic and side effects, can be taken for a long term without dependence, also can promote calcium absorption to make bones healthy, and has healthcare effects. The self-emulsifying EPA nutrient composition increases in-vivo absorption, and the addition of a calcium absorption promoting factor-vitamin K2 promotes the healthiness of the bones during therapy.